Summit Therapeutics Inc (NASDAQ: SMMT) on Friday, soared 5.82% from the previous trading day, before settling in for the closing price of $17.52. Within the past 52 weeks, SMMT’s price has moved between $2.05 and $33.89.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -28.65%. The company achieved an average annual earnings per share of 69.38%. With a float of $103.50 million, this company’s outstanding shares have now reached $737.09 million.
Let’s determine the extent of company efficiency that accounts for 105 employees. In terms of profitability, gross margin is 385.96%, operating margin of 77226.38%, and the pretax margin is 83760.85%.
Summit Therapeutics Inc (SMMT) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Summit Therapeutics Inc is 85.96%, while institutional ownership is 11.49%. The most recent insider transaction that took place on Mar 27 ’24, was worth 201,874. In this transaction Chief Executive Officer of this company bought 54,321 shares at a rate of $3.72, taking the stock ownership to the 24,923,800 shares. Before that another transaction happened on Mar 26 ’24, when Company’s Chief Executive Officer bought 30,000 for $3.75, making the entire transaction worth $112,500. This insider now owns 30,000 shares in total.
Summit Therapeutics Inc (SMMT) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.06 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 69.38% per share during the next fiscal year.
Summit Therapeutics Inc (NASDAQ: SMMT) Trading Performance Indicators
Summit Therapeutics Inc (SMMT) is currently performing well based on its current performance indicators. A quick ratio of 8.31 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.28, a number that is poised to hit -0.08 in the next quarter and is forecasted to reach -0.39 in one year’s time.
Technical Analysis of Summit Therapeutics Inc (SMMT)
Looking closely at Summit Therapeutics Inc (NASDAQ: SMMT), its last 5-days average volume was 2.36 million, which is a drop from its year-to-date volume of 3.48 million. As of the previous 9 days, the stock’s Stochastic %D was 45.25%. Additionally, its Average True Range was 1.28.
During the past 100 days, Summit Therapeutics Inc’s (SMMT) raw stochastic average was set at 39.04%, which indicates a significant decrease from 55.80% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 53.75% in the past 14 days, which was lower than the 116.58% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $19.82, while its 200-day Moving Average is $11.45. However, in the short run, Summit Therapeutics Inc’s stock first resistance to watch stands at $19.36. Second resistance stands at $20.17. The third major resistance level sits at $21.05. If the price goes on to break the first support level at $17.67, it is likely to go to the next support level at $16.79. Now, if the price goes above the second support level, the third support stands at $15.98.
Summit Therapeutics Inc (NASDAQ: SMMT) Key Stats
Market capitalization of the company is 13.67 billion based on 737,448K outstanding shares. Right now, sales total 0 K and income totals -614,930 K. The company made 0 K in profit during its latest quarter, and -56,250 K in sales during its previous quarter.
